Clontech Laboratories & TET Systems Announce the Broadening of Their License Agreement
The Tet-On 3G Inducible Expression System provides highly inducible, sensitive control of gene expression. It includes two novel components, the rights to which were acquired by TET in 2009: (i) an improved transcriptional activator developed by scientists at the Academic Medical Center at the University of Amsterdam (AMC) in the Netherlands, and (ii) a novel minimal Tet promoter developed at the University of Heidelberg in Germany.
Most read news
Organizations
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.